Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacokinetics Study of FBF001

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* subject between 21-40 years old~* with body mass index in the range 18 to 30 Kg/m2~Exclusion Criteria:~* Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, haematological, neurological, osteo-muscular, articular, psychiatric, systemic, ocular, or infectious disease, or signs of acute illness~* Any vaccination within three months before the inclusion~* Any vaccination against H5N1 virus~* Planned receipt of any vaccine during the study~* Any infectious disease within the month before the inclusion~* Any history of animal proteins allergy, animal allergy and/or any drug, food and pollen allergy~* Who has received blood or plasma derivatives (human or animal) in the three months preceding the initiation of the study~* Any medication within 14 days before the inclusion or within 5 times the elimination half-life or pharmacodynamic half-life of that drug

- Gender: MALE
- Minimum Age: 21 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- FBF001 (Type: EXPERIMENTAL): FBF001 must be administered by intravenous route during 1 hour. The dose must be calculated according to the body weight of the subject and diluted in sodium chloride 0.9%.~FBF001 is administered once during 1 day or once per day during 5 days.
- Placebo (Type: PLACEBO_COMPARATOR): The placebo must be administered by intravenous route during 1 hour. It administered once during 1 day or once per day during 5 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).